Compare ENVX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | NUVB |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | ENVX | NUVB |
|---|---|---|
| Price | $9.06 | $8.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $17.14 | $9.63 |
| AVG Volume (30 Days) | 6.5M | ★ 10.2M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,273,000.00 | $26,748,000.00 |
| Revenue This Year | $36.91 | $283.17 |
| Revenue Next Year | $117.80 | $340.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 45.98 | ★ 1137.19 |
| 52 Week Low | $5.27 | $1.54 |
| 52 Week High | $16.49 | $8.70 |
| Indicator | ENVX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 76.08 |
| Support Level | $7.27 | $7.46 |
| Resistance Level | $7.90 | $8.24 |
| Average True Range (ATR) | 0.55 | 0.62 |
| MACD | 0.26 | 0.13 |
| Stochastic Oscillator | 93.78 | 97.20 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.